Poster featuring TILT technology will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington DC, USA in November.
IL-2 in adoptive cell therapy – local production from an adenovirus vector instead of systemic administration results in safety and efficacy gains
